Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
12.04
+0.39 (3.35%)
Aug 25, 2026, 4:00 PM EDT - Market closed
Zevra Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 136.07 | 106.47 | 23.61 | 27.46 | 10.16 | 28.65 | |
Revenue Growth | 119.40% | 350.92% | -14.02% | 170.26% | -64.53% | 115.61% |
Cost of Revenue | 6.18 | 16.48 | 7.42 | 2.17 | 0.22 | 2.06 |
Gross Profit | 129.89 | 89.99 | 16.2 | 25.29 | 9.94 | 26.59 |
Selling, General & Admin | 74.73 | 77.71 | 54.92 | 35.09 | 15.61 | 9.23 |
Research & Development | 14.83 | 12.65 | 42.04 | 39.03 | 19.23 | 9.64 |
Amortization of Goodwill & Intangibles | 1.26 | 3.86 | 6.24 | 0.77 | - | - |
Operating Expenses | 90.82 | 94.22 | 103.2 | 74.89 | 34.84 | 18.86 |
Operating Income | 39.07 | -4.23 | -87 | -49.6 | -24.9 | 7.73 |
Interest Expense | -5.71 | -7.98 | -7.35 | -1.5 | -0.34 | -0.38 |
Interest & Investment Income | 10.18 | 6.95 | 2.18 | 4.54 | 1.51 | 0.26 |
Other Non Operating Income (Expenses) | -7.39 | 2.18 | 2.06 | -0.1 | 15.16 | -0.03 |
EBT Excluding Unusual Items | 36.15 | -3.09 | -90.12 | -46.66 | -8.57 | 7.59 |
Gain (Loss) on Sale of Investments | -0.2 | 0.15 | -0.02 | 0.61 | -0.58 | -0.01 |
Gain (Loss) on Sale of Assets | 43.31 | 148.33 | - | - | - | - |
Asset Writedown | - | -58.71 | - | - | - | - |
Other Unusual Items | -9.97 | - | - | - | - | -16.1 |
Pretax Income | 69.29 | 86.68 | -90.14 | -46.05 | -26.81 | -8.52 |
Income Tax Expense | 11.03 | 3.45 | 15.37 | - | -0.03 | 0.03 |
Net Income | 58.26 | 83.23 | -105.51 | -46.05 | -26.77 | -8.56 |
Preferred Dividends & Other Adjustments | 1.02 | 5.64 | - | - | - | 54.34 |
Net Income to Common | 57.25 | 77.59 | -105.51 | -46.05 | -26.77 | -62.9 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 57 | 55 | 46 | 35 | 34 | 30 |
Shares Outstanding (Diluted) | 60 | 57 | 46 | 35 | 34 | 30 |
Shares Change | 13.46% | 23.81% | 30.46% | 2.79% | 15.87% | 647.72% |
EPS (Basic) | 1.00 | 1.40 | -2.28 | -1.30 | -0.78 | -2.11 |
EPS (Diluted) | 0.96 | 1.35 | -2.28 | -1.30 | -0.78 | -2.11 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 32.62 | -2.43 | -69.67 | -33.83 | -18.81 | 10.34 |
Free Cash Flow Per Share | 0.55 | -0.04 | -1.51 | -0.95 | -0.55 | 0.35 |
Gross Margin | 95.46% | 84.52% | 68.59% | 92.09% | 97.81% | 92.81% |
Operating Margin | 28.71% | -3.98% | -368.47% | -180.63% | -245.07% | 26.98% |
Profit Margin | 42.07% | 72.87% | -446.85% | -167.69% | -263.48% | -219.54% |
Free Cash Flow Margin | 23.98% | -2.28% | -295.04% | -123.20% | -185.12% | 36.08% |
EBITDA | 40.55 | -0.18 | -80.61 | -48.6 | -23.96 | 7.99 |
EBITDA Margin | 29.80% | -0.17% | - | -176.97% | -235.78% | 27.87% |
D&A For EBITDA | 1.49 | 4.05 | 6.39 | 1.01 | 0.94 | 0.26 |
EBIT | 39.07 | -4.23 | -87 | -49.6 | -24.9 | 7.73 |
EBIT Margin | 28.71% | -3.98% | - | -180.63% | -245.07% | 26.98% |
Effective Tax Rate | 15.91% | 3.98% | - | - | - | - |